Skip to main content

ASTRO Issues Guidance Related to Partial Breast Irradiation

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 1, 2023.

By Elana Gotkine HealthDay Reporter

FRIDAY, Dec. 1, 2023 -- In a clinical practice guideline issued by the American Society for Radiation Oncology (ASTRO) published online Nov. 15 in Practical Radiation Oncology, recommendations are presented to inform best clinical practices on the use of partial breast irradiation (PBI).

Simona F. Shaitelman, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues convened a task force to address four questions related to appropriate indications and techniques for PBI as an alternative to whole breast irradiation (WBI). The guidelines were developed based on a systematic review, and recommendations were created using a predefined consensus-building methodology.

PBI is strongly recommended for patients with early-stage invasive breast cancer with grade 1 to 2 disease, estrogen receptor-positive histology, age 40 years or older, and tumor size ≤2 cm. The authors noted that using three-dimensional conformal radiation therapy, intensity-modulated radiation therapy, multicatheter brachytherapy, and single-entry brachytherapy to deliver PBI results in similar ipsilateral breast recurrence (IBR) as WBI with long-term follow-up. Due to underrepresentation of certain patient characteristics and tumor features in randomized controlled trials, the IBR risk for patients with these features could not be fully defined. Compared with WBI, intraoperative radiation therapy is associated with a higher IBR rate. Due to late toxicity concerns, a daily or every-other-day external beam PBI regimen is preferred over twice-daily regimens.

"These data should be driving a change in practice, and partial breast radiation should be a larger part of the dialogue when we consult with patients on decisions about how best to treat their early-stage breast cancer," Shaitelman said in a statement.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Inavolisib + Palbociclib-Fulvestrant Improves Survival in Advanced Breast Cancer

THURSDAY, Oct. 31, 2024 -- Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus palbociclib-fulvestrant in patients with...

Multigene Signature Can Help Tailor Chemo for Operable Triple-Negative Breast Cancer

WEDNESDAY, Oct. 30, 2024 -- For patients with operative triple-negative breast cancer, a multigene signature can help tailor adjuvant chemotherapy, according to a study published...

Guideline-Concordant Care Less Likely With Non-Hispanic Black Race

TUESDAY, Oct. 29, 2024 -- For older patients with breast cancer, non-Hispanic Black race is associated with increased odds of not receiving guideline-concordant care (GCC) and...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.